THE RS1801282 PPARG POLYMORPHISM DEPENDENT METABOLIC EFFECTS OF PIOGLITAZONE IN PATIENTS WITH OBESITY AND CONCOMITANT NAFLD by Shypulin, Vadym et al.
Original Research Article:
full paper




THE RS1801282 PPARG POLYMORPHISM DEPENDENT 
METABOLIC EFFECTS OF PIOGLITAZONE IN PATIENTS 
WITH OBESITY AND CONCOMITANT NAFLD
Vadym Shypulin
Department of Internal Medicine No. 11
shypulin@me.com
Nikolai Rudenko
Department of Internal Medicine No. 11
dok.don@hotmail.com
Oleksandr Martynchuk





15-A Belorusska str., Kyiv, Ukraine, 04119
alex.genetic@gmail.com
Vitaly Guryanov
Department of Health Management1
i_@ukr.net
Nataliia Melnyk 
Department of Internal Medicine No. 11
nataliya.g.melnyk@gmail.com
1Bogomolets National Medical University
13 T. Shevchenko blvd., Kyiv, Ukraine, 01601
Abstract
The aim: to investigate the metabolic effects of different treatment options in patients with obesity and concomitant 
non-alcoholic fatty liver disease (NAFLD) based on the presence of CG and GG genotypes PPARG rs1801282 (Pro12Ala) poly-
morphism in Ukrainians.
Materials and methods: 123 patients with NAFLD in combination with obesity 1, 2, 3 classes were included in the mo-
tivational weight loss program (5 visits, 3 months). The case group was treated with pioglitazone 15 mg / day, while the control 
group received only a program. Ultrasound steatometry, anthropometric and laboratory tests before and after treatment, genetic 
testing rs1801282 polymorphism in PPARG gene were performed.
Results: the carriers of CG and GG genotypes PPARG rs1801282 polymorphism had less high stimulated insulin levels com-
pared with groups of different genotypes (p<0.001). It was found pioglitazone effectiveness with significant difference in dynamics 
of CAP reduction (p<0.001) regardless of polymorphism. Dynamics of BMI decrease was the lowest in control group CC carries – 
–2.81 (–3.23; –2.39) kg (p<0.001) compared among other groups. Subjects from pioglitazone group with rs1801282 polymorphism 
carrying of CG and GG genotypes had significant differences in dynamics of fasting С-peptide decrease, serum uric acid reduction – 
–1.31 (–1.50; –1.13) µg/L and –165.3 (–182.80; –147.80) µmol/L (p<0.001) respectively compared among other groups. 
Conclusions: Better reduction of metabolic parameters during pioglitazone treatment of patients with obesity and con-
comitant NAFLD appears to be associated with carrying of CG and GG genotypes PPARG rs1801282 polymorphism.










Research concerning genetic polymorphisms of obesity and other metabolic risk factors 
for non-alcoholic fatty liver disease (NAFLD) is a quite popular area in understanding the key 
factors in the management of NAFLD treatment. Among the most studied polymorphisms 
common to obesity and NAFLD is the rs1801282 (Pro12Ala) polymorphism in the PPARG 
(peroxisome proliferator-activated receptor gamma) gene, which is involved in both patho-
genesis and treatment [1, 2]. PPARG2 is known to be most expressed in adipose tissue and 
macrophages, much less in the liver, skeletal muscle and, also much higher in the placenta. It 
is 5–10 times higher than the transcriptional activity of PPARG1, which is expressed in most 
tissues. It is clear that the expression of transcription factors that control fat metabolism is 
impaired in obese patients and NAFLD. In case of excessive ectopic expression of hepatic 
PPARG, the formation of triglycerides by the liver is enhanced [3]. Although activation of 
hepatic-specific PPARGs is steatogenic, treatment of genetically predisposed individuals or 
NAFLD/NASH induced by diet with PPARG ligands reduces steatosis [4, 5]. Nowadays, rec-
ommended for NASH treatment is only one drug – pioglitazone, particularly in T2D where it is 
registered [6]. 
The carries of G allele (CG and GG genotypes) Pro12Ala polymorphism in the PPARG 
gene have reduced lipoprotein lipase activity, leading to an increase in atherogenic low-density 
lipoproteins cholesterol, very low-density lipoproteins cholesterol, triglycerides, a decrease in 
high-density lipoproteins cholesterol and higher total cholesterol level while protecting against 
steatosis [7]. Furthermore, carrying of CG and GG genotypes is associated with a higher body 
mass index (BMI) and has a protective character for type 2 diabetes (T2D) in persons with less 
BMI and some features of food eating habits (saturated and/or trans-unsaturated fatty acids). 
Considering the role of the higher atherogenic coefficient, it is expected the giant numbers of 
cardiovascular disease events in patients with this phenotype.
Obesogenic environment inviolately leads to NAFLD development [8]. It is well known 
that an excessive amount of intrahepatic fat is owing by peripheral lipolysis from insulin resis-
tance (IR) due to impaired suppression of lipolysis that is abnormally provoked by stimulated 
insulin and consequently inhibited oppression of free fatty acid f lux in blood plasma after a 
meal [9]. Moreover, recent studies in animals confirm that serum uric acid vice versa contrib-
utes intrahepatic fat accumulation through hyperactivation of the polyol pathway of glucose 
metabolism [10]. Simultaneously, ferritin influences on glucose metabolism via modulation of 
secretion β-pancreatic cells [11]. Passive metabolic traits were not investigated in patients with 
obesity and concomitant NAFLD based on PPARG rs1801282 polymorphism in Ukrainians. 
Prior results with inconsistent longitudinal findings of multiple studies of the above-men-
tioned polymorphism are likely due to pleiotropic effects of PPARG gene and thus different 
affinity with PPARG agonists. 
The aim of this study was to investigate the metabolic effects of different treatment 
options in patients with obesity and concomitant NAFLD based on the presence of CG and 
GG genotypes PPARG rs1801282 polymorphism during the treatment with pioglitazone in 
Ukrainians.
2. Materials and methods
The study was conducted at Bogomolets National Medical University, Department of 
Internal Medicine No. 1 (Kyiv, Ukraine) in accordance with the Declaration of Helsinki and 
was approved by the Ethic Committee (Ref. No. 122/29.05.2019). The prospective interven-
tional study included 123 Ukrainians who were consulted in 2016–2020. Each patient signed 
an informed consent to be included in the study. Inclusion criteria: patients diagnosed with 
obesity using BMI 30-44.99 kg/m2 in combination with NAFLD (ALT≤2.5 ULN), deter-
mined by ultrasound steatometry (controlled attenuation parameter (CAP) ≥2.2 dB/cm), age – 
18–60 years. Exclusion criteria: hepatitis of different etiologies, type 1 and 2 diabetes, heart 
failure (NYHA class 2–4), history of bladder cancer in patients and the first line of inheri-
tance, other severe comorbidities.
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By randomization, patients were divided into two groups. All patients were offered a 
motivational weight loss program consisting of 5 doctor visits over a 3-month follow-up. The 
program included a modification of the patient’s lifestyle: a decrease in the patient’s energy 
diet by 500 kcal from physiological daily energy expenditure and his moderate physical ac-
tivity of 150–200 min per week (walking at a speed of 5–6 km/h). Self-report adherence and 
weight loss history with the help of questionnaires were conducted also. All patients under-
went genetic testing for the presence rs1801282 polymorphism in the PPARG gene, standard 
anthropometric measurements, laboratory screening and ultrasound steatometry before and 
after 3 months of treatment.
Clinical genetic stage of the research involved buccal epithelium sampling and genotype 
testing. DNA was extracted using AmpliPrime DNA-sorb-AM test system (Next-Bio LLC, 
Russia). PCR was carried out by ROTOR GENE 6000 analyzer (Corbett, Australia), using the 
SNP-EXPRESS-SHOT diagnostic kit by Liteh (Russia). 
Ultrasound steatometry was used to diagnose NAFLD with a Soneus P7 instrument 
(Ultrasign, Ukraine). The score of steatosis was determined by the results of US on a scale 
of CAP, which corresponded to the morphological scale of NAS (NAFLD activity score): 
light (S1 – 2.20–2.29 dB/cm), moderate (S2 – 2.30–2.90 dB/cm), heavy (S3 – more than 
2.90 dB/cm) [12, 13]. 
After 3 months of treatment the dynamics of ultrasound were studied (reduction of liver 
size, improvement of echostructure, decrease in CAP during treatment).
All patients underwent a 75 g oral glucose tolerance test (OGTT) according to the rec-
ommendations of the World Health Organization [14]. Subjects with a fasting glucose level of 
at least 7.0 mmol/L were ineligible for further follow-up testing. Venous blood samples were 
obtained directly before (0 min) and during 120 min the OGTT for determination of plasma 
glucose and insulin concentrations. Glucose and serum uric acid were measured by the hex-
okinase glucose-6-phosphate dehydrogenase method and colorimetric assay kit using «Co-
bas 6000; Roche Diagnostics» (Switzerland), respectively [15]. Insulin concentrations, serum 
C-peptide, ferritin was determined by immunochemical method with chemiluminescent detec-
tion of CLIA on an analyzer «Immulite; Siemens AG» (Germany) [16]. 
The diagnostic criteria for T2D from the International Diabetes Federation [17] and 
the World Health Organization [14] were used. The normal type in criteria for T2D was eval-
uated at less than 6.1 mmol/L of fasting plasma glucose levels and 7.8 mmol/L of glucose 
120 min levels. Impaired glucose tolerance (IGT) was assessed at less than 6.1 mmol/L of 
fasting plasma glucose levels and from 7.8 mmol/L to 11.0 mmol/L of glucose 120 min levels. 
The T2D was evaluated with a fasting glucose of 7.0 mmol/L and over or glucose 120 min of 
11.1 mmol/L and over. The normal ranges were counted up to 25 (acceptable 3–8) mIU/L for 
fasting insulin and 16–166 (acceptable up to 41) mIU/L for stimulated insulin. Fasting C-pep-
tide – 0.8–3.85 µg/L, C-peptide 2 hour after glucose load 3–9 µg/L took as normal.
Statistical processing of the obtained results was made by using the Statistical Pack-
age EZR v. 1.35 (R statistical software version 3.4.3, R Foundation for Statistical Computing, 
Vienna, Austria) [18]. Shapiro-Wilk test was performed to check the normality of the distri-
bution of the quantitative variables. The median (Me) and the interquartile range (QI–QIII) 
were calculated for non-normal distributed value. Since some variables did not follow a nor-
mal distribution, non-parametric methods were used for the analysis of the data. For the 
reduction in anthropometric and metabolic parameters the average value ( )X  and 95 % CI 
was calculated. All statistical tests were based on the two-tailed probability. The null hy-
pothesis was rejected at the significance level of p<0.05. Hardy-Weinberg equilibrium 
(HWE) online calculator was obtained from https://wpcalc.com/en/equilibrium-hardy-wein-
berg. Allele frequencies were determined by gene counting. A c2 test was used to test the 
HWE. Spearman’s rank correlation coefficient was used to estimate the degree of correla-
tion. For the statistical evaluation, the significance of the differences in mean values be-









The clinical characteristics of the study groups are shown in Table 1. There were no 
significant differences between these two groups in BMI, sex, age, fasting glucose and C-pep-
tide, glucose and insulin 120 min, HOMA-IR Index, ferritin, serum uric acid levels (p>0.05). 
The case group included 61 subjects with an average of fasting insulin 9.76 (7.67–12.53) mIU/L 
and CAP 2.61 (2.47–2.77) dB/cm levels, the control group consisted of 62 individuals with 
10.70 (9.59–12.39) mIU/L and 2.47 (2.28–2.69) dB/cm as an average fasting insulin and CAP 
levels respectively. The average CAP level was much higher and average fasting insulin le- 
vels – less high against such values in the control group. Thus, there were significant differenc-
es in fasting insulin and CAP levels before treatment (p=0.05; p=0.02) respectively as well as 
C-peptide 120 min levels (p=0.04). Another obtained result indicated the levels of stimulated 
insulin had a high correlation with serum uric acid (r=0.86, p<0.05) and CAP levels – a medi-
um correlation with HOMA-IR Index (r=0.60, p<0.01). 
At the same time, a significant difference in dynamics of CAP reduction in pioglitazone 
group compared with control one during treatment (p<0.001) is represented in Fig. 1. 
Table 1




Pioglitazone group (n=61) Control group (n=62)
BMI, kg/m2 33.4 (31.2–36.0) 32.6 (31.4–35.5) 0.53
Sex, male/ female 29/32 35/27 0.42
Age, years 42 (35–53.25) 42 (34–50) 0.45
Fasting plasma glucose, mmol/L 4.89 (4.54–5.40) 5.09 (4.63–5.37) 0.59
Plasma glucose t=120 min, mmol/L 5.0 (4.70–5.80) 5.1 (4.89–5.78) 0.53
Fasting plasma insulin, mIU/L 9.76 (7.67–12.53) 10.70 (9.59–12.39) 0.05
Plasma insulin t=120 min, mIU/L 54.89 (44.29–69.30) 57.08 (39.90–68.19) 0.82
Fasting serum С-peptide, µg/L 2.70 (2.45–3.06) 2.73 (2.52–2.94) 0.97
Serum С-peptide t=120 min, µg/L 6.89 (5.65–7.93) 7.55 (6.41–8.40) 0.04
HOMA-IR Index 2.78 (2.11–3.41) 2.84 (2.23–3.29) 0.75
Serum ferritin, µg/L 367.70 (341.4–384.4) 378.65 (361.2–387.0) 0.07
Serum uric acid, µmol/L 161.50 (109.5–273.0) 170.65 (130.1–275.33) 0.65
CAP, dB/cm 2.61 (2.47–2.77) 2.47 (2.28–2.69) 0.02
Note: p – level of statistical significance between groups; Me (QI–QIII ) – median value from lower to upper quartile (25 to 75 per-
centiles). Quantitative variables were compared by the Mann-Whitney test. Qualitative variables were compared by c2 test
At the start, we confirmed the benefits of pioglitazone treatment on CAP reduction 
regardless some differences in CAP before treatment. 
The distribution of alleles and genotypes in study groups is presented in Table 2. Al-
leles distribution matched with HWE expectation (pHWE=0.09). Both the distribution of geno-
types and alleles had no significant differences (pg=0.82; pa=0.97).
To manage patients with obesity and concomitant NAFLD we addressed the hypothesis that 
the influence of primary metabolic parameters during different treatment management on results 
in groups vary thus may provide more accurate insight to make treatment decision and also dose.
The results of multiple-pairwise comparison procedure in anthropometric and meta-
bolic parameters depending on the presence of PPARG rs1801282 (C>G) polymorphism before 
treatment and dynamics of treatment are summarized in Table 3, 4. As seen from the foregoing 
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Table 3, there were significant differences in carries of G allele before treatment in fasting insu-
lin (p<0.001) and C-peptide levels (p=0.04) compared with carries of CC genotype in case group 
patients and in insulin 120 min level (p<0.001) between groups with different genotypes. There-
fore, patients with CG and GG genotypes in case group had much higher fasting insulin and less 
high stimulated insulin levels, which could be associated with the expression of PPARG gene and 
activation of related transcriptional factors. Besides, they had basic higher BMI, fasting glucose, 
less high CAP levels, but the difference was not significant at all 4 groups (p>0.05). There was 
no significant difference in fasting glucose, C-peptide 120 min and ferritin levels between groups 
(p>0.05). The levels of glucose 120 min were not compared among groups, as there was no T2D in 
groups or IGT.
Fig. 1. Dynamics of CAP reduction after 3 months treatment in  
two groups Me (QI–QIII) – median value from lower to upper quartile (25 to 75 percentiles)
Table 2
The distribution of alleles and genotypes for PPARG rs1801282 (C>G) polymorphism in two groups
Variant
Pioglitazone group (n=61) Control group (n=62)
pHWE p
n % n %
Genotypes
CC 50 81.97 51 82.26
– 0.82CG 10 16.39 9 14.52
GG 1 1.64 2 3.23
Alleles
C 110 90.16 111 89.52
0.09 0.97
G 12 9.84 13 10.48
Note: n – number; pHWE – the rate of deviation of the allele frequencies from the HWE; p – level of statistical significance
As seen from the Table 4, dynamics of decrease were positive in all groups with the 
most significant difference in case group with CG and GG genotypes in insulin 120 min le-
vels (p=0.02) compared with control one with CG and GG genotypes and in fasting C-peptide 
(p<0.001), serum uric acid levels (p<0.001) compared with other groups. Interestingly, that 








and control groups with difference regardless of polymorphism (p<0.001) although BMI de-
crease was the lowest in control group CC carries (p<0.001). 
Table 3
Results of multiple-pairwise comparison procedure of anthropometric and metabolic parameters depending 
on the presence of PPARG rs1801282 (C>G) polymorphism before treatment
Parameter 
Me (QI–QIII)
p Pioglitazone group 





Control group with 
CC genotype (n=51)
Control group with 
CG+GG genotype 
(n=11)



















































































Note: p – level of statistical significance in difference between the groups; Me (QI–QIII) – median value from lower to upper quartile 
(25 to 75 percentiles). Nonparametric variables were compared by – Kruskal-Wallis test. Dunn’s multiple comparison tests were 
used for post-hoc test. p1 – significant difference from the pioglitazone group with the CC genotype, p<0.05; p2 –significant diffe-
rence from the pioglitazone group with the CG and GG genotypes, p<0.05; p3 – significant difference from the control group with 
the CC genotype, p<0.05; p4 – significant difference from the control group with the CG and GG genotypes, p<0.05
Table 4
Results of multiple-pairwise comparison procedure of reduction in anthropometric and metabolic parameters 
dynamics depending on the presence of PPARG rs1801282 (C>G) polymorphism
Parameter
X  (95 % CI)
p Pioglitazone group 
with CC genotype 
(n=50)
Pioglitazone group 
with CG+GG  
genotype (n=11)
Control group with 
CC genotype (n=51)
Control group with 
CG+GG genotype 
(n=11)
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Note: p – level of statistical significance in difference between the groups; X  (95 % CI) – the average value of reduction. Non-
parametric variables were compared by – Kruskal-Wallis test. Dunn’s multiple comparison tests were used for post-hoc test. 
p1 – significant difference from the pioglitazone group with the CC genotype, p<0.05; p2 – significant difference from the pioglita-
zone group with the CG and GG genotypes, p<0.05; p3 – significant difference from the control group with the CC genotype, p<0.05; 
p4 – significant difference from the control group with the CG and GG genotypes, p<0.05
4. Discussion
Findings from our research demonstrate that in participants undergoing modification of 
their lifestyles were some significant differences in the average fasting insulin, C-peptide 120 min 
and CAP levels before treatment. Features of insulin degradation with short half-life period 
(3–5 min) [19] or secretion type (normal type, insulin-late type, insulin- and glucose-late type, 
insulin-very late type) as well as binding with peripheral receptors could explain these differences 
of fasting insulin [20]. Despite knowledge that peripheral C-peptide levels are more accurately 
reflect portal insulin secretion than measurement of peripheral insulin because of 3–4 times longer 
half-time life [21], however ranges can vary between laboratories because of lack standardization.
It must be mentioned that less high stimulated insulin level before treatment can be inter-
preted as fewer IR in carries of CG and GG genotypes. NAFLD patients with rs1801282 polymor-
phism in case group carries of CG and GG genotypes had significant differences in reduction of 
insulin 120 min levels –18.14 (–21.14; –15.15) mIU/L (p=0.02) compared control group such carries. 
Therefore, it must be mentioned that insulin 120 min response after treatment with pioglitazone 
changed greatly in CG and GG genotype patients via presumable modulation of the binding af-
finity of receptor agonist with PPARG and PPARA. Fasting C-peptide and serum uric acid levels 
decreased mostly –1.31 (–1.50; –1.13) µg/L and –165.30 (–182.80; –147.80) µmol/L (p<0.001) re-
spectively in carries of CG and GG genotypes among all groups. Generally, the case group had sig-
nificant differences in dynamics of CAP reduction (p<0.001) regardless of polymorphism as well 
as the control group carries of CC genotype had the lowest BMI reduction – –2.81 (–3.23; –2.39) kg 
(p<0.001) related to variant gene dependent mechanism.
It was revealed also significant correlation coefficients between CAP levels and HOMA-IR 
index as well as stimulated insulin levels and serum uric acid levels indicating tight link with met-
abolic patterns observed. By the way, the reduction of serum uric acid also can help to evaluate 
decreased IR. The study brought out comprehension of the insulin response to pioglitazone in study 
groups based on PPARG rs1801282 polymorphism. On the other hand, despite likely widespread 
opinion about the protection of the G allele Pro12Ala polymorphism PPARG gene against liver 
steatosis and steatohepatitis [22], we detected higher ferritin levels in carries of this phenotype 
although without achieving significant differences between groups (p>0.05). Thus, the role of this 
variant PPARG gene for NAFLD is still unclear [23].
Continuation of Table 4
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Generally, we obtained results that confirmed the effectiveness of pioglitazone on steatosis 
reduction. Additionally, there are some inconsistent and controversial results after treatment (it is 
not shown in certain table) and in dynamics based on rs1801282 polymorphism between groups.
Finally, we announced similar findings in some studies but they could not be applicable for 
all ethnic subgroups [24]. The number of works devoted to this polymorphism had opposite and 
poor data. Therefore, most authors have not found consistent answers as well. 
Study limitations. Nevertheless, our research is not without limitations. We investigated only 
PCR real-time polymorphism, but it might be interesting to study gene expression levels depend-
ing on the allelic variant. Despite the lack of recommendations to use ultrasound steatometry by 
EASL-EASD-EASO Clinical Practice Guidelines (2016) [6], we assessed the score steatosis without 
biopsy and NASH grading as we decided it may be insecure and sometimes harmful for patients. 
However, casual ultrasound is a simple screening method for assessing the presence of steatosis, 
supplementary measurement of CAP gives more information. In a way if it has been done accurately, 
steatometry can improve the assessment of steatosis score. Thus, is also reliable and relevant at all. 
Prospects for further research. Further compare between groups for finding the reasons of 
CAP differences before treatment and study the association between the effectiveness of treatment 
NAFLD with pioglitazone in patients with obesity and PPARG rs1801282 polymorphism is needed.
5. Conclusions
Based on the above analysis, the present study demonstrated:
1) PPARG rs1801282 polymorphism carrying of CG and GG genotypes might be associated 
with less high stimulated insulin level thus IR state;
2) The lowest dynamics of BMI decrease appears to be dependent on CC genotype of con-
trol group in contrast of much higher fasting C-peptide and serum uric acid reduction in carries of 
CG and GG genotypes in case of treatment these groups with pioglitazone;
3) The study has shown better pioglitazone effectiveness in dynamics of CAP reduction 
regardless of PPARG gene variant, further study of this association with genotype is necessary.
This article is carried out within the framework of scientific research work: «Optimization 
of Diagnostic and Treatment of Digestive Diseases in Comorbidity Conditions».
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